September 7th, 2010
TENX BIOPHARMA REINITIATES ENROLLMENT IN PIVOTAL PHASE III, CTCL TRIAL
TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients.

July 14th, 2010
PHASE II ZANOLIMUMAB TRIAL DATA IN PTCL PATIENTS PUBLISHED
Results were published in the British Journal of Haematology for a Phase II trial of zanolimumab (HuMax-CD4) treatment in relapsed or refractory non-cutaneous peripheral T cell lymphoma patients.

May 6th, 2010
TENX BIOPHARMA TO PRESENT AT BIO 2010 IN CHICAGO
CEO of TenX Biopharma, Inc., Gardiner F. Smith, presented at the international BIO conference held in Chicago, May 3rd-6th.